CasInvent
CasInvent Pharma is a biotechnology spin-off from Masaryk University that develops proprietary small-molecule inhibitors of the Casein Kinase 1 (CK1) family. These inhibitors target cellular mechanisms responsible for resistance in various malignancies, including Acute Myeloid Leukemia (AML) and solid tumors such as melanoma and prostate cancer. The company focuses on advanced preclinical development to advance these candidate compounds into clinical trials for patients with resistant tumors.
Visit websiteBrno, Czech Republic
Biotechnology
Oncology
Pharmaceuticals
Healthtech
Funding summary
- Total raised
- €1.3M
- Funding rounds
- 1
Investors in CasInvent
Investors on record for CasInvent. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like CasInvent?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors